Efficacy of Selenium-Enriched Tuna Nuggets on Cardiometabolic Subfractions and Inflammation in Ischemic Cardiomyopathy: A Randomized Controlled Trial
DOI:
https://doi.org/10.65761/pjcr.2026.50Keywords:
Cardiomyopathies, Functional Food, Selenium, Tuna, Lipids / blood, C-Reactive Protein, Randomized Controlled Trials as TopicAbstract
Background: Ischemic cardiomyopathy (ICM) progression is closely linked to chronic systemic inflammation and metabolic dysregulation. Bioactive functional foods provide a practical strategy to alter these underlying cardiometabolic risk factors. Ischemic cardiomyopathy (ICM) progression is closely linked to chronic systemic inflammation and metabolic dysregulation. Bioactive functional foods provide a practical strategy to alter these underlying cardiometabolic risk factors.
Methods: A 13-week randomized controlled trial was conducted in Mufti Mehmood Memorial Teaching Hospital, Pakistan, enrolling 124 stable ICM patients. Participants were randomized in a 1:1 ratio to either an intervention group receiving daily selenium-enriched tuna nuggets (30.6% protein, 1.8% fat; n = 62) or a control group receiving standard dietary care (n = 62). Anthropometric parameters, fasting plasma glucose, serum lipids, and high-sensitivity C-reactive protein (hs-CRP) were measured at baseline and post-intervention. Mediation analysis quantified nutrient-specific contributions.
Results: At week 13, the intervention group demonstrated significant reductions in body weight, BMI, fasting glucose, total cholesterol, LDL-C, and triglycerides compared with controls. HDL-C increased significantly, while hs-CRP decreased, indicating reduced systemic inflammation. Mediation analysis showed that the nugget’s multi-nutrient matrix accounted for 24–53% of observed clinical improvements. Sensory evaluation further demonstrated excellent product palatability, supporting the intervention’s potential clinical and acceptability benefits
Conclusion: : Selenium-enriched tuna nuggets represent a safe, highly acceptable, and effective functional dietary adjunct to improve anthropometrics, optimize lipid subfractions, and suppress chronic systemic inflammation in patients with ICM.
References
1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global public health burden of heart failure. Cardiovasc Res. 2023;118(17):3272-3284. doi:10.1093/cvr/cvac013.
2. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528. doi:10.1161/cir.0000000000000746.
3. Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39(2):210-218. doi:10.1016/s0735-1097(01)01738-7.
4. Ellis SG. Ischemic cardiomyopathy: an overview of medical and surgical management. In: Interventional Cardiology. New York: Thieme; 2022. doi:10.1055/b-0039-173858.
5. Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16(9):435. doi:10.1007/s11883-014-0435-z.
6. Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301(6):H2181-H2190. doi:10.1152/ajpheart.00554.2011.
7. Patel VB, Robbins MA, Topol EJ. C-reactive protein: a "golden marker" for inflammation and coronary artery disease. Cleve Clin J Med. 2001;68(6):521-534.
8. Bomer N, Grote Beverborg N, Hoes MF, de Jong AM, Goris M, Bakker SJL, et al. Selenium deficiency in heart failure: a biomarker of impaired mitochondrial function and predictor of mortality. Eur J Heart Fail. 2023;25(11):1980-1990. doi:10.1002/ejhf.2990.
9. Feingold KR. Dyslipidemia in patients with diabetes. Endotext [Internet]. South Dartmouth: MDText.com, Inc.; 2023. doi:10.1007/978-3-031-13177-6_14.
10. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128.
11. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi:10.1161/cir.0000000000001073.
12. Hansen MK, Mortensen MB, Olesen KKW, Thrane PG, Maeng M. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. Lancet Reg Health Eur. 2024;36:100774. doi:10.1016/j.lanepe.2023.100774.
13. Bhatnagar A. Environmental determinants of cardiovascular disease. Circ Res. 2017;121(2):162-180. doi:10.1161/circresaha.117.306458.
14. Freeman AM, Morris PB, Barnard N, Esselstyn CB, Ros E, Agatston A, et al. Trending cardiovascular nutrition controversies. J Am Coll Cardiol. 2017;69(9):1172-1187. doi:10.1016/j.jacc.2016.10.086.
15. Chakraborty K, Raola VK, Joy M, Makkar F. Nutritional attributes in the fillet of skipjack tuna (Katsuwonus pelamis) from the Arabian Sea near the south-west coast of India. J Mar Biol Assoc UK. 2017;97(2):419-432. doi:10.1017/s0025315416000527.
16. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. doi:10.1161/CIR.0000000000001123.
17. Al-Mubarak AA, Grote Beverborg N, de Boer RA, van der Meer P, Bomer N. Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common path. Free Radic Biol Med. 2024;210:144-156. doi:10.1016/j.freeradbiomed.2023.11.009.
18. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115. doi:10.1042/bst20160474.
19. Girotti AW. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res. 1998;39(8):1529-1542. doi:10.1016/s0022-2275(20)32182-9.
20. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as a toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis. 2005;15(4):316-328. doi:10.1016/j.numecd.2005.05.003.
21. Riccioni G. Carotenoids and cardiovascular disease. Curr Atheroscler Rep. 2009;11(6):434-439. doi:10.1007/s11883-009-0065-z.
22. Al-Mubarak AA, van der Meer P, Bomer N. Selenium, selenoproteins, and heart failure: current knowledge and future perspectives. Curr Heart Fail Rep. 2021;18(3):122-131. doi:10.1007/s11897-021-00511-4.
23. Benstoem C, Goetzenich A, Kraemer S, Borosch S, Manzanares W, Hardy G, et al. Selenium and its supplementation in cardiovascular disease-what do we know? Nutrients. 2015;7(5):3094-3118. doi:10.3390/nu7053094.
24. Rayman MP. Selenium and human health. Lancet. 2012;379(9822):1256-1268. doi:10.1016/s0140-6736(11)61452-9.
25. Burk RF, Hill KE. Selenoprotein P-expression, functions, and roles in mammals. Biochim Biophys Acta. 2015;1850(11):2256-2264. doi:10.1016/j.bbagen.2009.03.026.
26. Baseline parameters of the non-communicable disease risk factor surveillance in Pakistan: a population-based cross-sectional study. Lancet Reg Health Southeast Asia. 2023;16:100234. doi:10.1016/j.lansea.2023.100234.
27. Global burden of cardiovascular diseases and risks, 1990-2022: JACC Focus Seminar. J Am Coll Cardiol. 2023;82(25):2350-2424. doi:10.1016/j.jacc.2023.11.007.
28. Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all-cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008;168(4):404-410. doi:10.1001/archinternmed.2007.74.
29. Rees K, Hartley L, Day C, Flowers N, Clarke A, Stranges S. Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD009671. doi:10.1002/14651858.cd009671.pub2.
30. Raygan F, Behnejad M, Ostadmohammadi V, Bahmani F, Mansournia MA, Karamali F, et al. Selenium supplementation lowers insulin resistance and markers of cardio-metabolic risk in patients with congestive heart failure: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2018;120(1):33-40. doi:10.1017/s0007114518001253.
31. Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol. 2012;8(3):160-171. doi:10.1038/nrendo.2011.174.
32. Jafar TH, Chaturvedi N, Pappas G. Prevalence of overweight and obesity and their association with hypertension and diabetes mellitus in an Indo-Asian population. CMAJ. 2006;175(9):1071-1077. doi:10.1503/cmaj.060464.
33. Harshfield EL, Fauman B, Stacey D, Paul DS, Ziemek D, Ong RM, et al. Genome-wide analysis of blood lipid metabolites in over 5000 South Asians reveals biological insights at cardiometabolic disease loci. BMC Med. 2021;19(1):232. doi:10.1186/s12916-021-02087-1.
34. Callender T, Woodward M, Roth G, Farzadfar F, Lemarie JC, Gicquel S, et al. Heart failure care in low-and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2014;11(8):e1001699. doi:10.1371/journal.pmed.1001699.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Zahid Imran, Manzar Ayub, Arif Mumtaz
This work is licensed under a Creative Commons Attribution 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
